Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan

Figure 4 Hepatitis C virus treatment uptake by year from 2011 to 2019. The annual numbers of people living with human immunodeficiency virus (PLWH) who received interferon-based therapy were unchanged from 2012 to 2016. With the introduction of direct-acting antivirals (DAAs) since 2016, the number of PLWH receiving DAAs increased annually, especially in 2019, when the restrictions on the DAA reimbursement were lifted and all hepatitis C virus viremic patients could be treated with DAAs. DAA: Direct-acting antiviral; IFN: Interferon.